Let's Talk About Sex

Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

• Clinical trials excluded women with many comorbidities (e.g., unstable medical conditions).
• Real-world effectiveness in broader populations may differ from trial results.
• Patient satisfaction with treatment can vary widely.
• Some women report significant improvement in sexual desire and distress.
• Others discontinue due to side effects or lack of meaningful benefit.
• Adherence to daily dosing is a challenge for some patients.
• The bedtime dosing schedule is intended to mitigate side effects like dizziness.
• Taking it with a high-fat meal can increase absorption and side effect risk.
• Should be taken on an empty stomach, at least 2 hours after a high-fat meal.

sufentanil SLsufentanil SL and flibanserin both increase sedation. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.sufentanil SL, flibanserin.

sufentanil SL and flibanserin both increase sedation. sulconazolesulconazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sulconazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tacrolimustacrolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Before using flibanserin

rabeprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ranolazineranolazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ranolazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifabutin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampinrifampin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Already Own This Product?

rifampin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifapentinerifapentine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifapentine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. risperidonerisperidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, risperidone.

Black Box Warnings

risperidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rucaparibrucaparib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rucaparib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. scopolamine intranasalscopolamine intranasal and flibanserin both increase sedation. scopolamine intranasal and flibanserin both increase sedation. tacrolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

talazoparibflibanserin increases levels of talazoparib by P-glycoprotein (MDR1) efflux transporter.

Why is this medication prescribed?

pentamidinepentamidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentamidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbitalpentobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Strong CYP3A4 inducers substantially decrease flibanserin systemic exposure.pentobarbital and flibanserin both increase sedation. pentobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Incidence not known

phenobarbitalphenobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoinphenytoin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pilocarpinepilocarpine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

CNS Activity

pilocarpine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pimozidepimozide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, pimozide. pimozide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pravastatinpravastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with P-gp inhibitors may increase talazoparib exposure. Monitor for increased talazoparib adverse reactions and adjust dose as necessary.

flibanserin increases levels of talazoparib by P-glycoprotein (MDR1) efflux transporter.

Adult Dosing .

pravastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. prednisoloneprednisolone will increase the level or effect of flibanserin by aldehyde dehydrogenase inhibition. prednisolone will increase the level or effect of flibanserin by aldehyde dehydrogenase inhibition. primaquineprimaquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primaquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Who should not use Addyi?

primidoneprimidone will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidone will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. progesterone micronizedprogesterone micronized will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. progesterone micronized will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. propofolpropofol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

IN CLINICAL TRIALS1, WOMEN ON ADDYI EXPERIENCED:

propofol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. quinineflibanserin increases levels of quinine by P-glycoprotein (MDR1) efflux transporter. Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if coadministered with flibanserin.quinine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. flibanserin increases levels of quinine by P-glycoprotein (MDR1) efflux transporter. rabeprazolerabeprazole will increase the level or effect tadalista 2 5 of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tamoxifentamoxifen will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tamoxifen will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tecovirimattecovirimat will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes.tecovirimat will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Flibanserin is classified as a centrally acting serotonergic agent.
• It is not a testosterone-based therapy, unlike some other treatments.
• The FDA approval was based on studies showing increased sexual desire in women.
• The medication can cause sleep disturbances, including somnolence.
• Flibanserin has a potential for drug interactions with CYP3A4 inhibitors.
• It is recommended to start treatment at least 4 weeks before expecting improvement.
• Discontinuation of the drug normally leads to the loss of effects.
• The drug's efficacy is modest compared to some male sexual dysfunction drugs.
• Initiation of therapy involves screening for contraindications.

Monitor sensitive CYP3A4 substrates for effectiveness if coadministered. tecovirimat will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.

Monitor for adverse effects if coadministered with sensitive substrates of these enzymes. temsirolimustemsirolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. temsirolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. teniposideteniposide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Further information

selegilineselegiline will libido booster for women increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. selegiline will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. selegiline transdermal will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sirolimusflibanserin increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if coadministered with flibanserin.sirolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What are some other side effects of this drug?

sodium oxybatesodium oxybate and flibanserin both increase sedation. sodium oxybate and flibanserin both increase sedation. sparsentansparsentan will decrease the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. sparsentan will decrease the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.

How do I store and/or throw out this drug?

St John's WortSt John's Wort will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. St John's Wort will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.stiripentol will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Consider reducing the dose vardenafil canada of CYP2C19 substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.stiripentol, flibanserin. teniposide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. testosteronetestosterone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.